How to reduce radiation-related toxicity in patients with cancer of the head and neck

Current Oncology Reports

Volumn 8, Issue 2, 2006, Pages 140-145

  Garden, Adam S ^a   Lewin, Jan S ^b   Chambers, Mark S ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTIBIOTIC AGENT; CEVIMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; GROWTH FACTOR; ISEGANAN; PALIFERMIN; PILOCARPINE; PLACEBO;

CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; MUCOSA INFLAMMATION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PHYSICS; REVIEW; SPEECH THERAPY; SWALLOWING; XEROSTOMIA;

AMIFOSTINE; ANTI-INFECTIVE AGENTS; DEGLUTITION DISORDERS; FIBROSIS; FREE RADICAL SCAVENGERS; GROWTH SUBSTANCES; HEAD AND NECK NEOPLASMS; HUMANS; MUCOSITIS; OXIDATIVE STRESS; RADIATION DOSAGE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY, CONFORMAL; XEROSTOMIA;

EID: 33645547910     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0049-x     Document Type: Review

References (30)

1. Bernier J, Domenge C, Ozsahin M, et al.: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350:1945-1952.
2. Forastiere AA, Goepfert H, Maor M, et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098.
3. Cooper JS, Pajak TF, Forastiere AA, et al.: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350:1937-1944.
4. Fu KK, Pajak TF, Trotti A, et al.: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48:7-16.
5. Trotti A, Bellm LA, Epstein JB, et al.: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 2003, 66:253-262.
6. Sonis ST: The pathobiology of mucositis. Nat Rev Cancer 2004, 4:277-284.
7. Trotti A, Garden A, Warde P, et al.: A multinational randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 2004, 58:674-681.
8. Donnelly JP, Bellm LA, Epstein JB, et al.: Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis 2003, 3:405-412.
9. Spielberger R, Stiff P, Bensinger W, et al.: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004, 351:2590-2598.
10. Brizel DM, Le QT, Rosenthal D, et al.: Phase 2 study of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer treated with standard (SRT) or hyperfractionated irradiation (HRT) & concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2002, 54(Suppl 2):285.
11. Brizel DM, Wasserman TH, Henke M, et al.: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000, 18:3339-3345.
12. Buentzel L Micke O, Adamietz IA, et al.: Intravenous amifostine during chemoradiotherapy for head-and-neck cancer. a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 2005 Oct 20; [Epub ahead of print].
13. Buntzel J, Schuth J, Kuttner K, et al.: Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 1998, 6:155-160.
14. Antonadou D, Pepelassi M, Synodinou M, et al.: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 52:739-737.
15. Rubenstein EB, Peterson DE, Schubert M, et al.: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004, 100(9 suppl):2026-2046.
16. Chambers MS, Garden AS, Kies MS, et al.: Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004, 26:796-807.
17. Wasserman TH, Brizel DM, Henke M, et al.: Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized phase III trial. Int J Radiat Oncol Biol Phys 2005, 63:985-990.
18. Eisbruch A, Kim H, Terrell J, et al.: Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001, 50: 695-704.
19. Garden AS, Morrison WH, Rosenthal DI, et al.: Target coverage for head and neck cancers treated with IMRT: Review of clinical experiences. Semin Radiat Oncol 2004, 14:103-109.
20. Eisbruch A, Ten Haken RK, Kim HM, et al.: Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999, 45:577-587.
21. Blanco AI, Chao KS, El Naqa I, et al.: Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:1055-1969.
22. Jabbari S, Kim H, Feng M, et al.: Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: Initial report. Int J Radiat Oncol Biol Phys 2005, 63:725-731.
23. Johnson JT, Ferretti GA, Nethery WJ, et al.: Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993, 329:390-395.
24. Chambers MS, Posner MR, Jones CU, et al.: Two phase III clinical studies of cevimeline for post-radiation xerostomia in patients with head and neck cancer [abstract]. Proc ASCO 2005, 23 (16 S):500.
25. Eisbruch A, Lyden T, Bradford CR, et al.: Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 53:23-28.
26. Eisbruch A, Schwartz M, Rasch C, et al.: Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004, 60:1425-1439.
27. Kotz T, Abraham S, Beitler JJ, et al.: Pharyngeal transport dysfunction consequent to an organ-sparing protocol. Arch Otolaryngol Head Neck Surg 1999, 15:383-388.
28. Chen A, Frankowski R, Bishop-Leone J, et al.: The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: The M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 2001, 127:870-876.
29. Lazarus CL, Logemann JA, Pauloski BR, et al.: Swallowing disorders in head and neck cancer patients treated with radiotherapy and adjuvant chemotherapy. Laryngoscope 1996, 106:1157-1166.
30. Pauloski BR, Logemann JA: Impact of tongue base and posterior pharyngeal wall biomechanics on pharyngeal clearance in irradiated postsurgical oral and oropharyngeal cancer patients. Head Neck 2000, 22:120-131.